Biocon diversifies business model, enters digital therapeutic segment
To launch Insulia for at-home management of diabetes in collaboration with Voluntis21-07-2020
21-07-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins21-07-2020
Biocon to do phase-4 trial of Covid drug
Biocon to do phase-4 trial of Covid drugThe Drug Controller gave Biocon an restricted emergency use authorisation to try out and continue to treat Covid-19 patients and then do a phase IV trial to corroborate the findings.17-07-2020
BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 066660 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer15-07-2020
Biocon share climbs 5% as firm to launch COVID-19 drug Itolizumab
Biocon share has risen 7.78% in the last 5 days of gains. The stock opened with a gain of 2.03% and later touched an intraday high of Rs 435.25, rising 4.98% against yesterday's close of Rs 414.60 on BSE14-07-2020
Biocon to launch COVID-19 drug; stock jumps 5%
Biocon said the approval of Itolizumab, from the DCGI, is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi.14-07-2020
Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients
The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in the country.12-07-2020
BIOCON LTD. - 532523 - Shareholding for the Period Ended June 30, 2020
Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here11-07-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon's Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients11-07-2020
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2020.09-07-2020